Research programme: targeted lipid transport therapeutics - Amarin

Drug Profile

Research programme: targeted lipid transport therapeutics - Amarin

Alternative Names: AMR-102/3; AMR-103; AMR-109; Combinatorial lipids programme - Amarin; TLT programme - Amarin

Latest Information Update: 05 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amarin Corporation
  • Class
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - CNS disorders

Highest Development Phases

  • No development reported Cognition disorders; Memory disorders; Parkinson's disease

Most Recent Events

  • 05 Nov 2010 No development reported - Preclinical for Cognition disorders in United Kingdom (unspecified route)
  • 05 Nov 2010 No development reported - Preclinical for Memory disorders in United Kingdom (unspecified route)
  • 05 Nov 2010 No development reported - Preclinical for Parkinson's disease in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top